


jc864 U.S. PTO
07/12/00

07-13-00


A

Certificate of Mailing	
Date of Deposit <u>JULY 12, 2000</u>	Label Number: <u>EL509046799US</u>
I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231.	
<u>Luis Cruz</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

jc857 U.S. PTO
09/614264
07/12/00

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 CFR §1.53(b)	
Attorney Docket Number	50036/028002
Applicant	Peter Lohse et al.
Title	C-TERMINAL PROTEIN TAGGING
PRIORITY INFORMATION:	
This application claims priority from United States provisional patent application 60/143,339, filed July 12, 1999.	
APPLICATION ELEMENTS:	
Cover sheet	1 page
Specification	16 pages
Claims	4 pages
Abstract	1 page
Drawing	12 sheets
Combined Declaration and POA, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application ["**SERIAL NUMBER**"] and the entire disclosure of the prior application is considered as being part of the disclosure of this new application and is hereby incorporated by reference therein.	3 pages
Statement Deleting Inventors	0 pages
Sequence Statement	0 pages
Sequence Listing on Paper	0 pages
Sequence Listing on Diskette	0 disk

09644264 071200

Small Entity Statement, which is: <input type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input checked="" type="checkbox"/> A copy from prior application 60/143,339, and such small entity status is still proper and desired.	1 page
Preliminary Amendment	0 pages
IDS	0 pages
Form PTO 1449	0 pages
Cited References	0 references
Recordation Form Cover Sheet and Assignment	0 pages
Assignee's Statement	0 pages
English Translation	0 pages
Certified Copy of Priority Document	0 pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$345	\$ 345.00
Excess Claims Fee: 31 - 20 x \$9	\$ 99.00
Excess Independent Claims Fee: 2 - 3 x \$39	
Multiple Dependent Claims Fee: \$130	
Total Fees:	\$ 444.00
<input checked="" type="checkbox"/> Enclosed is a check for \$444.00 to cover the total fees. <input type="checkbox"/> Charge [**AMOUNT**] to Deposit Account No. 03-2095 to cover the total fees. <input type="checkbox"/> The filing fee is not being paid at this time. <input checked="" type="checkbox"/> Please apply any other charges, or any credits, to Deposit Account No. 03-2095.	
CORRESPONDENCE ADDRESS:	
Karen L. Elbing, Ph.D. Reg. No. 35,238 Clark & Elbing LLP 176 Federal Street Boston, MA 02110	Telephone: 617-428-0200 Facsimile: 617-428-7045
<div style="display: flex; justify-content: space-between;"><div>Signature </div><div>12 July 2000 Date</div></div>	

Applicant or Patentee : Peter Lohse and Michael McPherson
 Serial or Patent No. : not yet assigned
 Filed or Issued : herewith
 Title : C-TERMINAL PROTEIN TAGGING

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: Phyllos, Inc.

Address of Small Business Concern: 128 Spring Street, Lexington, MA 02421

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled ADDRESSABLE PROTEIN ARRAYS by inventors Robert G. Kuimelis and Richard Wagner described in

- ☒ the specification filed herewith.
☐ application serial no. ["APPLICATION NUMBER"], filed ["FILING DATE"].
☐ patent no. ["PATENT NUMBER"], issued ["ISSUE DATE"].

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Assignee Name:

Assignee Address:

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.

Name: Ashley Lawton, Ph.D.

Title: President and CEO

Address: Phyllos, Inc., 128 Spring Street, Lexington, MA 02421

Signature:  Date: 7/4/99

09614264 "071200

C-TERMINAL PROTEIN TAGGING

Cross Reference To Related Applications

5 This application claims the benefit of the filing date of provisional application, U.S.S.N. 60/143,339, filed July 12, 1999.

Background of the Invention

In general, the invention relates to methods of labeling proteins.

Covalent conjugates of polypeptides with non-peptide "labels" or "tags" form a useful class of reagents in protein research. A conjugate is usually intended to retain the native properties of the protein while gaining a new, non-native property due to the label. Biotinylation, for example, permits proteins to be separated, quantified, or immobilized by mechanisms based on the strong interaction of biotin with avidin or streptavidin (Bayer & Wilchek (1990) Protein Biotinylation, Meth. Enzymol. 184:138-160). Fluorescent or metal-chelating groups can also be introduced to generate newly modified proteins.

It would be convenient to be able to introduce a non-protein label as the protein is produced, but this is only sometimes feasible, for example, if the peptide can be produced by chemical synthesis, and is impractical when the protein is produced biologically. Generally, the conjugate must be formed by treating the peptide with a functional group-specific reagent that contains the label. Moreover, unless the peptide contains only one group attacked by the reagent, this procedure generally yields a mixture of products. This random form of labeling is sometimes adequate, but it is often preferable to modify a protein at a single specified site and

to employ the modified product in purified form. For such cases, it would be valuable to have a method of directing the modifying group to a single, preselected location. Such a precisely targeted modification is termed site-directed protein tagging.

5

Summary of the Invention

In general, the invention features a protein having a covalently bonded puromycin tag, the tag being positioned at the C-terminal end of the protein.

10 In preferred embodiments, the tag is a small molecule (for example, biotin); the tag is a detectable label (for example, fluorescein, rhodamine, or BODIPY, or derivatives thereof); the tag is a functional group (for example, a functional group having a reactivity orthogonal to the reactivity of one of the protein's functional groups); the tag is a tether for attachment to a solid support (for example, a column, bead, or chip); the tag is one member of a specific binding pair; the tag is a phenyl diboronic acid derivative; the puromycin tag further
15 includes a nucleotide sequence positioned between the tag and the puromycin; and the nucleotide sequence is between about 1-200 nucleotides in length.

In a related aspect, the invention features a method for C-terminal protein tagging, involving (a) providing a nucleic acid sequence encoding the protein; (b) translating the sequence under conditions in which translation stalls at
20 the 3' end of the sequence, forming a stalled translation complex; and (c) contacting the stalled translation complex with a puromycin tag under conditions in which the puromycin tag is covalently bonded to the C-terminus of the protein.

In preferred embodiments, the tag is attached to the 5'-hydroxy group of puromycin; the tag is attached to the 5'-hydroxy group of the puromycin through a

phosphate group; the nucleic acid sequence encoding the protein contains no stop codons; the translation step is carried out in the substantial absence of at least one translation release factor; the 3'-end of the nucleic acid sequence encoding the protein is covalently linked to a DNA oligomer; the tag is a small molecule (for example, biotin); the tag is a detectable label (for example, fluorescein, rhodamine, or BODIPY, or a derivative thereof); the tag is a functional group; the protein has a first functional group and the tag is a second functional group, wherein the first functional group has a reactivity orthogonal to the reactivity of the second functional group; the tag is a tether for attachment to a solid support (for example, a column, bead, or chip); the tag is one member of a specific binding pair; the tag is a phenyl diboronic acid derivative; the puromycin tag further includes a nucleotide sequence positioned between the tag and the puromycin; and the nucleotide sequence is between about 1-200 nucleotides in length.

By a "protein" is meant any two or more naturally occurring or modified amino acids joined by one or more peptide bonds. "Protein," "peptide," and "polypeptide" are used interchangeably herein.

By a "puromycin tag" is meant puromycin having a covalently bonded structural or functional moiety which is not native to the puromycin molecule and which is chosen from the group consisting of a detectable label, a chemically reactive functional group, a small molecule, a protein or peptide, a peptoid, a naturally occurring or non-naturally occurring polymer, a solid-phase bound tether, a carbohydrate, or a nucleic acid (preferably, of between about 1-200 nucleotides) which does not encode the protein to which the puromycin tag is itself covalently linked. By a "nucleic acid" is meant any two or more covalently bonded, naturally occurring or modified nucleotides and includes DNA, RNA, and PNA. Preferred

puromycin-nucleic acid tags include 5'-C-C-puromycin-3'.

By a "small molecule" is meant a molecule having a molecular weight of approximately 2000 Daltons or less, preferably, 1500 Daltons or less, more preferably, 1000 Daltons or less, and, most preferably, 500 Daltons or less.

5 By a "functional group" is meant any moiety of, or arrangement of atoms in, a molecule which exhibit some chemical reactivity.

10 The present invention provides a number of advantages over current chemical and enzymatic protein-tagging methods. For example, the tag is introduced in the final step of translation on the ribosome. This modification is advantageous because tagged proteins may be generated in a single preparative step. In addition, the tag is introduced in translation buffer under conditions which enhance protein stability. Again, this provides for increased product yield and optimized protein quality. In particular, although several schemes for N-terminal (Drijfhout et al. (1990) Anal. Biochem. 187: 349-354; Wetzel et al. (1990) Bioconjugate Chem. 1: 114-122) and C-terminal (Schwarz et al. (1990) Meth. Enzymol. 184: 160-162; Rose et al. (1989) Peptides 1988 (G. Jung and E. Bayer, eds.) pp. 274-276, Walter de Gruyter & Co., New York) tagging have been described, many of these methods involve a tagging step that is carried out under conditions which disrupt protein structure. For example, modification at 20 non-physiological pH and temperature or in the presence of non-aqueous solvents or chemicals, followed by purification of the modified protein, disrupts folding thus leading to a non-functional product. In contrast, the present tagging method is performed under native conditions. Finally, in yet another advantage, the present invention enables the introduction of a tag regioselectively at the C-terminus of a

protein, facilitating the production of native proteins carrying desired C-terminal structural or functional elements in a simple and efficient way.

The C-terminally tagged polypeptides and proteins produced by the methods of the present invention may be used in any appropriate technique, for example, in any affinity purification method, protein detection method (for example, using proteins having C-terminal fluorescein tags), structure function or protein dynamics analyses (for example, using proteins having C-terminal reporter tags), pharmaceutical analyses (for example, using proteins having detectable C-terminal tags which allow for a determination of cellular protein uptake or cellular localization), or protein display technology (for example, using solid phase tags to generate protein arrays on microchips).

Other features and advantages will be apparent from the following detailed description and from the claims.

Brief Description of the Drawings

FIGURE 1 is a schematic illustration of the preparation of a C-terminally tagged protein according to the present invention.

FIGURE 2 is a schematic illustration of an exemplary method for the attachment of a tag to a puromycin or oligonucleotide-puromycin (X_n -puromycin) derivative through a 5'-phosphodiester linkage.

FIGURE 3 is a schematic illustration of an exemplary method for the attachment of tags to puromycin or X_n -puromycin with 5'-terminal modified amino or thiol linkers.

FIGURE 4 is a schematic illustration of an X_n -puromycin-5'-phosphate carrying a 5'-tethered biotin.

FIGURE 5 is a schematic illustration of an X_n -puromycin 5'-phosphate carrying both biotin and fluorescein groups.

FIGURE 6 is a schematic illustration of the reversible attachment of a protein-linked X_n -puromycin-5'-phosphate carrying a 5'-tethered phenyl diboronic acid to a salicylhydroxamic acid derivative.

FIGURE 7 is a schematic illustration of an X_n -puromycin-5'-phosphate carrying a 5'-ketone group.

FIGURE 8 is a schematic illustration of an exemplary method for the attachment of a 5'-terminal amino X_n -puromycin to an N-hydroxy succinimide activated agarose gel (AffiGel).

FIGURE 9 is a schematic illustration of an exemplary method for the attachment of a 5'-terminal amino X_n -puromycin to an isothiocyanate-functionalized chip surface, for example, for the purpose of directed protein immobilization.

FIGURE 10 is a schematic illustration of an X_n -puromycin 5'-phosphate dimer linked through a polyethylene oxide chain.

FIGURE 11 is a schematic illustration of an exemplary method for the production of a 1,2-aminothiol puromycin derivative.

FIGURE 12 is a schematic illustration of an X_n -puromycin-5'-phosphate carrying a 5'-terminal hydrazide group.

Detailed Description

The present invention makes use of puromycin, an antibiotic that mimics the aminoacyl end of tRNA, as a vehicle to introduce a tag at the C-terminus of a protein. The puromycin acts as a translation inhibitor by entering

the ribosomal A site and accepting the nascent protein as a result of the peptidyl transferase activity of the ribosome (Monro & Marcker (1967) J. Mol. Biol. 25: 347-350; Monro & Vazquez (1967) J. Mol. Biol. 28: 161-165). The resulting peptidyl-puromycin molecule contains a stable amide linkage between the peptide
5 and the O-methyl tyrosine portion of the puromycin.

A desired tag is linked to the puromycin moiety in such a way that binding as well as peptidyl acceptor functionality of the puromycin is only slightly decreased or is not decreased at all. Following translation, binding of the tagged puromycin by the ribosome followed by peptidyl transfer onto the primary amino
10 group of puromycin yields the desired C-terminally tagged protein. This technique is shown schematically in Figure 1.

Different positions of puromycin can serve as anchor points for attachment of tags, although puromycin functional groups not involved in ribosome binding represent preferred anchor points for attachment. In one
15 particular example, it has been shown that the 5'-hydroxymethyl group of puromycin does not contribute to ribosome binding (Vince et al. (1981) J. Med. Chem. 24: 1511). In addition, nucleic acids carrying a 3'-terminal puromycin have been shown to bind to the ribosome. Accordingly, the 5'-hydroxy group of puromycin is a preferred position for attachment of a desired tag (Szostak et al.,
20 WO 98/31700; Roberts & Szostak (1997) Proc. Natl. Acad. Sci. USA 94: 12297-12302).

The attachment of additional nucleotides (preferably, between about 1-200 nucleotides) at the 5'-hydroxymethyl group of puromycin may, in some cases, further enhance the ability of puromycin to enter the ribosomal A site and to act as
25 an effective tRNA substitute. No particular sequence of nucleotides is required for

These derivatives include puromycin or X_n -puromycin linked to small molecules, for example, X_n -puromycin-5'-phosphate carrying a tethered biotin derivative (Figure 4); such a puromycin or X_n -puromycin tag may be used to attach a C-terminal biotin label to a protein, for example, for affinity purification. In a further example, a puromycin or X_n -puromycin tag may act as a bifunctional reagent by using a puromycin or X_n -puromycin derivative which contains both attachment and detection groups, for example, as shown in Figure 5. In this example, an X_n -puromycin derivative is tethered through its 5'-phosphate to both biotin and fluorescein moieties using standard oligonucleotide synthesis techniques. Attachment groups may include, without limitation, biotin, phenyl diboronic acid/salicylhydroxamic acid, 1,2-amino thiol, or ketone. Detection groups may include, without limitation, fluorescein or derivatives thereof, rhodamine or derivatives thereof, or BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene, Molecular Probes, Eugene, OR) or derivatives thereof.

In a further example, a puromycin or X_n -puromycin 5'-phosphate carrying a phenyl diboronic acid (PDBA) derivative may also be used to label the C-terminus of a peptide or protein for the purpose of purification or immobilization, as shown, for example, in Figure 6. This reaction is carried out, for example, according to the manufacturer's instructions (Linx™ AP system, Invitrogen, Carlsbad, CA). In this example, the PDBA moiety interacts specifically with a salicylhydroxamic acid derivative to form a covalent complex (Linx™ AP system, Invitrogen, Carlsbad, CA). The interaction is reversible under certain pH conditions.

The scheme in Figure 3 outlines the synthesis of puromycin or X_n -puromycin tags which include a terminal modification that introduces a terminal

amino or thiol functionality into the puromycin or X_n -puromycin intermediate.

These reactions are again carried out as described above for Figure 2. As illustrated in Figure 7, these reactive moieties are then used to introduce non-protein functional groups, for example, a ketone, into the puromycin or

5 X_n -puromycin tag.

The synthetic scheme illustrated in Figure 3 may also be used to link puromycin to a solid phase, as shown in Figure 8. The solid phase may be any appropriate solid support including, without limitation, any column, plate, tube, bead, or chip. In the example illustrated in Figure 8, a 5'-terminal amino

10 functionalized puromycin or X_n -puromycin is used to derivatize an N-hydroxysuccinimide-activated agarose support (for example, Affi-Gel 10 or 15; Biorad, Hercules, CA) to generate an immobilized puromycin or X_n -puromycin derivative where, in this example, the solid support is the tag. This step is carried out according to the manufacturer's instructions (Affi-Gel; Biorad, Hercules, CA).
15 The puromycin or X_n -puromycin tethered to the solid phase may then be utilized in the purification and/or immobilization of peptides or proteins.

A puromycin or X_n -puromycin derivative with the appropriate terminal reactivity may also be used to derivatize a functionalized chip surface. The resulting "puromycin chip" may then be utilized for the direct attachment of
20 peptides or proteins on the chip surface upon contact with stalled ribosome complexes, as illustrated in Figure 9. In this example, a 5'-amino terminated X_n -puromycin derivative is used to functionalize a chip surface premodified with isothiocyanate groups (as described, for example, in Kuimelis et al., U.S.S.N. 09/282,734, entitled Addressable Protein Arrays, filed March 31, 1999; and
25 Kuimelis et al., WO 99/51773). The tethered puromycin then directs the

attachment of proteins through their C-terminus upon reaction with stalled ribosome complexes.

In yet another embodiment, puromycin may be linked to polymers. In one particular example, puromycin may be attached to an oligonucleotide using previously described methods (Szostak et al., WO 98/31700; Szostak et al., U.S.S.N. 09/247,190 (1999); Roberts & Szostak (1997) Proc. Natl. Acad. Sci. USA 94:12297-12302) for the purpose of sequence-specific hybridization to a solid phase.

An appropriate puromycin or X_n -puromycin tag may also be used for the preparation of protein-protein conjugates. In one example, a puromycin or X_n -puromycin dimer (Figure 10) may be added to stalled ribosome complexes to generate protein homodimers. Puromycin or X_n -puromycin dimers are prepared as described above for Figure 2 using a second puromycin or puromycin derivative as a tag.

In an alternative synthetic scheme, protein-polymer conjugates may be prepared using a step-wise approach. In the first step, a puromycin or X_n -puromycin derivative carrying a 5'-cysteinol moiety is used to introduce a 1,2-aminothiol reactive group into a protein. An example of the preparation of this modified protein is outlined in Figure 11. In this example, a puromycin or X_n -puromycin derivative carrying a 5'-terminal thiol moiety is alkylated with a suitable protected N-terminal cysteinyl peptide carrying a thiol-reactive maleimide group at its C-terminus (as described, for example, in Boeckler et al. (1998) Bioorg. Med. Chem. Lett. 8:2055-2058). In the second step, polymers (for example, proteins, nucleic acids, or unnatural polymers) or a solid phase (for example, a column, plate, tube, bead, or chip) carrying a thiolester group are linked

to the 1,2-aminothiol-tagged protein under physiological conditions using an orthogonal ligation strategy, as described, for example, in Methods for the Preparation of Nucleic Acid-Protein Conjugates, Dawson et al. (1994) Science 266: 776; Ni et al. (1998) J. Am. Chem. Soc. 120: 1645; and McPherson et al. (1999) Syn. Lett. S1: 978-980.

Alternatively, a puromycin or X_n -puromycin derivative carrying a 5'-terminal hydrazide group, as shown in Figure 12, may be used to introduce a C-terminal hydrazide nucleophile into the protein (Lohse et al., DNA-Protein Fusions and Uses Thereof, U.S.S.N. 60/110,549; U.S.S.N. 09/453,190 (1999); and WO 00/32823). Reaction of the hydrazide with a carbohydrate aldehyde or ketone group under physiological conditions may be used to generate protein-carbohydrate conjugates (as described, for example, in Gahmberg & Tolvanen (1994) Meth. Enzymol 230: 32-44).

To maximize the yield of the C-terminally tagged product, the tag is preferably attached to the full-length peptide or protein following translation of the open reading frame. This can be achieved by stalling the ribosome as an mRNA-ribosome-peptidyl complex after translation of the coding sequence. Ribosome stalling at the 3'-end of the open reading frame may be accomplished by any of a number of different methods. In one preferred approach, the message is engineered to be devoid of stop codons. As a result, release factors cannot bind, and the ribosome stalls (see, for example, Hanes & Plueckthun (1997) Proc. Natl. Acad. Sci. USA 94: 4937-4942). In another preferred approach, a DNA oligomer may be linked to the end of the message causing the ribosome to pause; this technique is described in Szostak et al., WO 98/31700; Szostak et al., U.S.S.N. 09/247,190 (1999); and Roberts & Szostak (1997) Proc. Natl. Acad. Sci. USA 94:

12297-12302). Alternatively, an in vitro translation lysate may be utilized which is devoid of release factors, as described in Lipovsek et al., Methods for Optimizing Cellular RNA-Protein Fusion Formation, U.S.S.N. 60/096,818; U.S.S.N. 09/374,962 (1999); and WO 00/09737.

5 The yield of the reaction of tagged puromycin with stalled ribosomes depends on the K_d of the puromycin derivative for the peptidyl transferase site, the concentration of tagged puromycin, and reaction conditions like buffer, temperature, and time. For example, in a preferred approach, the synthetically prepared puromycin derivative may be incubated under conditions known to
10 stabilize stalled ribosomes (see, for example, Hanes & Plueckthun (1997) Proc. Natl. Acad. Sci. USA 94: 4937-4942). The concentration of tagged puromycin supplied to the stalled ribosomes should preferably be above the K_d of tagged puromycin for the ribosomal peptidyl transferase. Concentrations of 5'-tagged puromycin derivatives in the low mM range (or even the low μM range) allow
15 efficient incorporation of the tag, considering the K_d of unmodified puromycin is in the micromolar range (see, for example, Pestka (1974) Meth. Enzymol. 30: 479-488; Vince et al. (1986) J. Med. Chem. 29: 2400-2403).

Following ribosome-catalyzed peptidyl transfer onto bound puromycin, the tagged protein may be released by addition of washing buffer containing
20 EDTA (see, for example, Hanes & Plueckthun (1997) Proc. Natl. Acad. Sci. USA, vol. 94, pp. 4937-4942). If desired, the tagged protein may then be purified using any appropriate biochemical purification protocol. In a preferred technique, the tag itself may be used to isolate the protein, for example, by affinity chromatography. Simple washing procedures may also be utilized if the
25 puromycin is tethered to a solid phase; in this approach, the tagged protein is

retained on the solid support and impurities removed in the wash solution.

Experimental Results

The *myc* epitope was chosen as an example to highlight the general tagging strategy described above. *Myc* dsDNA was generated by standard methods of PCR to include a 5'-T7 promoter for in vitro synthesis of mRNA using T7 polymerase and a deletion mutant of the tobacco mosaic virus 5'-UTR to induce efficient translation initiation in rabbit reticulocyte lysates. The 3'-end of the *myc* construct was devoid of stop codons to prevent protein release from the ribosome.

Transcription of the *myc* PCR product (using the MegaSHORTscript kit, Ambion) gave large quantities of RNA using T7 RNA polymerase. Purified RNA was then subjected to a splinted ligation reaction with a 5'-phosphorylated dA₃₀ oligonucleotide catalyzed by T4 DNA ligase. The 3'-dA₃₀ region facilitates ribosomal stalling and thereby increases the proportion of RNA-ribosome-protein complexes available for labeling. The purified *myc*-dA₃₀ construct was then translated in rabbit reticulocyte lysate (Ambion) with ³⁵S-methionine and stalled under high salt conditions (500 mM KCl, 20 mM MgCl₂).

Biotin-TEG-dCdC-puromycin (130 μM) was then added to the stalled translation reaction and labeling was allowed to take place. Biotin-TEG-dCdCdA was used as a control. The radiolabeled *myc* peptide was then isolated by immunoprecipitation with an anti-*myc* monoclonal antibody (Chemicon) and protein A sepharose (Sigma). Control and C-terminally-labeled peptide were then applied to a microscope slide prefunctionalized with NeutrAvidin™ (Pierce). Visualization by phosphorimaging revealed the biotin-dependent immobilization of *myc* epitope to the chip surface; no significant label was associated with the

negative control.

In a separate set of experiments, similar tagging of the fibronectin type III domain was also carried out to demonstrate the utility of the present tagging strategy for the immobilization of proteins with well-defined structural folds.

5 Fibronectin is a large multi-domain protein that plays a fundamental role in cell-cell interactions and extracellular matrix formation. The repeating domains display immunoglobulin-like features that are widely involved in mammalian molecular recognition. A DNA construct of the tenth repeat of the human fibronectin type III domain (8 kDa, 10Fn3) was created that included a region
10 encoding an N-terminal His₆ tag in addition to 5'-T7 promoter and TMV UTR regions.

Transcription (MegaSCRIPT, Ambion) of the ¹⁰F_n3 PCR product gave large amounts of RNA for subsequent enzymatic ligation to a dA₃₀ oligonucleotide. Translation in rabbit reticulocyte lysate, stalling, and labeling
15 with biotin-TEG-dCdC-puromycin were performed as outlined in the *myc* experiment. ¹⁰F_n3 protein was isolated from excess biotinylated puromycin analogue by affinity chromatography on a Co²⁺-NTA column (Talon™, Clontech). Application of ¹⁰F_n3 to a chip surface prespotted with NeutrAvidin™ protein and phosphorimaging analysis revealed the presence of radiolabeled ¹⁰F_n3.

20 The above experiments demonstrated that puromycin-mediated in vitro attachment of labels to the C-termini of peptides or proteins is a powerful technique for the regiospecific introduction of non-natural functionality into biomolecules. The puromycin analogues can be synthesized using standard oligonucleotide chemistry to include, for example, fluorophores, spin labels,
25 purification handles, or a combination thereof. One distinct advantage of this

approach is that labeling is performed under in vitro conditions that are compatible with maintaining the biological activity of the protein. Moreover, this tagging approach is amenable to a high throughput format of protein labeling for screening for biomolecules of therapeutic interest.

5

Other Embodiments

Other embodiments are within the claims.

All publications, patents, and patent applications mentioned herein are hereby incorporated by reference.

What is claimed is:

Claims

1. A protein having a covalently bonded puromycin tag, said tag being positioned at the C-terminal end of said protein.

2. The protein of claim 1, wherein said tag is a small molecule.

5 3. The protein of claim 2, wherein said small molecule is biotin.

4. The protein of claim 1, wherein said tag is a detectable label.

5. The protein of claim 4, wherein said detectable label is fluorescein, rhodamine, or BODIPY, or derivatives thereof.

6. The protein of claim 1, wherein said tag is a functional group.

10 7. The protein of claim 1, wherein said protein has a first functional group and said tag is a second functional group and wherein said first functional group has a reactivity orthogonal to the reactivity of said second functional group.

8. The protein of claim 1, wherein said tag is a tether for attachment to a solid support.

15 9. The protein of claim 8, wherein said solid support is a column, bead, or chip.

10. The protein of claim 1, wherein said tag is one member of a specific binding pair.

11. The protein of claim 10, wherein said tag is a phenyl diboronic acid derivative.

12. The protein of claim 1, wherein said puromycin tag further comprises a nucleotide sequence positioned between said tag and said puromycin.

13. The protein of claim 12, wherein said nucleotide sequence is between about 1-200 nucleotides in length.

14. A method for C-terminal protein tagging, comprising
(a) providing a nucleic acid sequence encoding said protein;
(b) translating said sequence under conditions in which translation stalls at the 3' end of said sequence, forming a stalled translation complex; and
(c) contacting said stalled translation complex with a puromycin tag under conditions in which said puromycin tag is covalently bonded to the C-terminus of said protein.

15. The method of claim 14, wherein said tag is attached to the 5'-hydroxy group of said puromycin.

16. The method of claim 15, wherein said tag is attached to the 5'-hydroxy group of said puromycin through a phosphate group.

17. The method of claim 14, wherein said nucleic acid sequence encoding said protein contains no stop codons.

18. The method of claim 14, wherein said translation step is carried out in the substantial absence of at least one translation release factor.

5 19. The method of claim 14, wherein the 3'-end of said nucleic acid sequence encoding said protein is covalently linked to a DNA oligomer.

20. The method of claim 14, wherein said tag is a small molecule.

21. The method of claim 20, wherein said small molecule is biotin.

22. The method of claim 14, wherein said tag is a detectable label.

10 23. The method of claim 22, wherein said detectable label is fluorescein, rhodamine, or BODIPY, or a derivative thereof.

24. The method of claim 14, wherein said tag is a functional group.

25. The method of claim 14, wherein said protein has a first functional group and said tag is a second functional group and wherein said first functional
15 group has a reactivity orthogonal to the reactivity of said second functional group.

26. The method of claim 14, wherein said tag is a tether for attachment

to a solid support.

27. The method of claim 26, wherein said solid support is a column, bead, or chip.

28. The method of claim 14, wherein said tag is one member of a
5 specific binding pair.

29. The method of claim 28, wherein said tag is a phenyl diboronic acid derivative.

30. The method of claim 14, wherein said puromycin tag further comprises a nucleotide sequence positioned between said tag and said puromycin.

10 31. The method of claim 30, wherein said nucleotide sequence is between about 1-200 nucleotides in length.

C-TERMINAL PROTEIN TAGGING

Abstract of the Disclosure

In general, the invention features proteins having covalently bonded C-terminal puromycin tags and methods for their production.

\\Ntserver\documents\50036\50036.028002 Utility Application.wpd

Preparation of C-terminally tagged protein




Figure 1

002720-49247960





Figure 2



(Glen Research, Sterling, VA)





Figure 3




Figure 4





Figure 5



where Y= solid phase, small molecule, protein etc.

Figure 6




Figure 7




Figure 8




Figure 9




Figure 10






Figure 11

PG=protecting group

AA=amino acid




Figure 12

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled C-TERMINAL PROTEIN TAGGING, the specification of which

☒ is attached hereto.

☐ was filed on _____ as Application Serial No. _____
and was amended on _____.

☐ was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

FOREIGN PRIORITY RIGHTS: I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
			Yes/No

PROVISIONAL PRIORITY RIGHTS: I hereby claim priority benefits under Title 35, United States Code, §119(e) and §120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status
60/143,339	July 12, 1999	Pending

NON-PROVISIONAL PRIORITY RIGHTS: I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the

COMBINED DECLARATION AND POWER OF ATTORNEY

claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Filing Date	Status

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bieker-Brady, Ph.D. Reg. No. 39,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, Mary Rose Scozzafava, Ph.D., Reg. No.36,268, James D. DeCamp, Ph.D., Reg. No. 43,580, Sean J. Edman, Reg. No. 42,506.

Address all telephone calls to: Karen L. Elbing, Ph.D. at 617/428-0200.

Address all correspondence to: Karen L. Elbing, Ph.D. at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Peter Lohse	50 Golden Ball Road Weston, MA 02493	50 Golden Ball Road Weston, MA 02493	Switzerland
Signature:			Date:

COMBINED DECLARATION AND POWER OF ATTORNEY

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Michael McPherson	142 Butler Avenue Providence, RI 02906	142 Butler Avenue Providence, RI 02906	Great Britain
Signature:			Date:

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Robert G. Kuimelis	21 Malbert Road Brighton, MA 02135	21 Malbert Road Brighton, MA 02135	United States
Signature:			Date: